Staphylococcal nuclease domain-containing protein 1 (SND1) (SND1)

Staphylococcal nuclease domain-containing protein 1 (SND1), also known as Tudor-SN or p100, is a multifunctional protein that plays a critical role in gene expression regulation at both transcriptional and post-transcriptional levels (UniProt KB - Q7KZF4). It is characterized by four staphylococcal nuclease (SN) domains and a Tudor domain, which facilitate its interactions with DNA, RNA, and proteins (PubMed: 24510034). SND1 acts as a transcriptional coactivator and is a key component of the RNA-induced silencing complex (RISC), where it promotes the degradation of hyper-edited miRNA precursors (PubMed: 30143548). In oncology, SND1 is frequently overexpressed and correlates with poor prognosis in various malignancies, including hepatocellular carcinoma and colon cancer, by promoting cell proliferation, metastasis, and chemoresistance (PubMed: 24510034). Therapeutic strategies focus on small molecule inhibitors that target the active site of the SN domains to block its nuclease activity and protein-protein interactions (PubMed: 25103497). While no drugs are currently FDA-approved, experimental inhibitors like 3',5'-deoxythymidine bisphosphate (pdTp) and its derivatives have shown promise in preclinical models by disrupting the oncogenic signaling pathways mediated by SND1 (PubMed: 25103497).

Other names

Tudor-SNp100Tudor domain-containing protein 11TDRD11100 kDa coactivator

Competitive inhibition of the staphylococcal nuclease (SN) domain active site, which prevents RNA binding and cleavage, thereby disrupting the RNA-induced silencing complex (RISC) and oncogenic transcriptional coactivation.